<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749879</url>
  </required_header>
  <id_info>
    <org_study_id>ZP-008</org_study_id>
    <nct_id>NCT00749879</nct_id>
  </id_info>
  <brief_title>Crossover Study of the Safety and PK Properties of Proellex®</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Single-Center, Unblinded, Single-Dose, Five-Way Crossover Study of the Safety and PK Properties of Proellex®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the PK of 25 mg and 50 mg of Proellex from 2 different suppliers in the fed
      and fasting states.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to evaluate the pharmacokinetic properties of two doses (25 mg and 50
      mg) of Proellex® formulated with microcrystalline cellulose (MCC) from 2 different suppliers
      in the fed and fasting states.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2008</start_date>
  <completion_date type="Actual">October 23, 2008</completion_date>
  <primary_completion_date type="Actual">October 23, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Proellex</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>Maximum observed concentration of Proellex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last of Proellex</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>Area under the plasma concentration curve from time 0 to the last measurable plasma concentration time point, up to 72 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Proellex</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>Time to maximum plasma occurrence of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity of Proellex</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>Area under the plasma concentration curve from time 0 to extrapolated to infinity, calculated by summing the area under the curve from time zero to the time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) of Proellex</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>Time to maximum plasma occurrence of T1/2, calculated as ln(2)/Elimination rate constant.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>25 mg AMCC fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose
Fed State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg AMCC fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose
Fasting State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg AMCC fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose
Fed State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg AMCC fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose
Fasting State</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg SMCC fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose
Fasting State</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex</intervention_name>
    <description>25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting</description>
    <arm_group_label>25 mg AMCC fasting</arm_group_label>
    <arm_group_label>25 mg AMCC fed</arm_group_label>
    <arm_group_label>50 mg AMCC fasting</arm_group_label>
    <arm_group_label>50 mg AMCC fed</arm_group_label>
    <arm_group_label>50 mg SMCC fasting</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be able to speak, read, and understand English and be willing and able to
             provide written informed consent in English on an Institutional Review Board (IRB)

          -  Premenopausal women aged 18-34, inclusive, with body mass index between 18 and 35,
             inclusive

          -  Women of child-bearing potential must be willing to use effective non-hormonal,
             double-barrier method contraception during the study period and for a minimum of 30
             days after discontinuation of the study medication. Women who have had a hysterectomy
             will be allowed into the study

          -  Must have a negative urine pregnancy test at screening

          -  Able to swallow gelatin capsules

          -  Medically normal subjects with no significant abnormal findings at the screening
             physical examination as evaluated by the Principal Investigator that would interfere
             with the subject participating this study

          -  Must have agreed to not attempt to become pregnant at any time during study
             participation or for 30 days thereafter

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Symptomatic uterine fibroids or endometriosis

          -  Past or present history of any significant cardiovascular, renal, or hepatic disease
             requiring ongoing medical therapy or clinical intervention

          -  Past or present history of thrombophlebitis, thromboembolic disorders, or
             cerebrovascular accident

          -  Abnormal screening visit vital signs or clinical laboratory evaluation considered
             clinically significant by the Principal Investigator

          -  Significant organ abnormality or disease (based on the Principal Investigator's
             judgment) that would in the opinion of the Principal Investigator exclude the subject
             from participating

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Chan</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>July 3, 2014</results_first_submitted>
  <results_first_submitted_qc>January 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2019</results_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>Pharmacokinetics</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 17 participants, 4 did not meet inclusion/exclusion criteria, and 1 participant enrolled as a spare was not needed, resulting in their involvement in the study being terminated. The remaining 12 participants completed all five study treatments of Proellex.</recruitment_details>
      <pre_assignment_details>Each of the 12 participants were randomly assigned a unique sequence of the following 5 following open-label treatments of Proellex
25 mg formulated with AMCC (fed state)
25 mg formulated with AMCC (fasting state)
50 mg formulated with AMCC (fed state)
50 mg formulated with AMCC (fasting state)
50 mg formulated with SMCC (fasting state)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Proellex</title>
          <description>in randomly assigned sequences, all study participants received 5 open-label treatments of Proellex: 25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fed State Proellex; 25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects enrolled</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Proellex</title>
        <description>Maximum observed concentration of Proellex</description>
        <time_frame>Up to 72 hours post-dose</time_frame>
        <population>12 subjects received all 5 treatments</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg AMCC Fed</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O2">
            <title>25 mg AMCC Fasting</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O3">
            <title>50 mg AMCC Fed</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O4">
            <title>50 mg AMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O5">
            <title>50 mg SMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose Fasting State</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Proellex</title>
          <description>Maximum observed concentration of Proellex</description>
          <population>12 subjects received all 5 treatments</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485.6" spread="151.3"/>
                    <measurement group_id="O2" value="876.7" spread="201.9"/>
                    <measurement group_id="O3" value="912.9" spread="157.6"/>
                    <measurement group_id="O4" value="1322.5" spread="154.5"/>
                    <measurement group_id="O5" value="1346.7" spread="148.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-last of Proellex</title>
        <description>Area under the plasma concentration curve from time 0 to the last measurable plasma concentration time point, up to 72 hours.</description>
        <time_frame>Up to 72 hours post dose</time_frame>
        <population>All 12 subjects received each treatment</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg AMCC Fed</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O2">
            <title>25 mg AMCC Fasting</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O3">
            <title>50 mg AMCC Fed</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O4">
            <title>50 mg AMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O5">
            <title>50 mg SMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose Fasting State</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last of Proellex</title>
          <description>Area under the plasma concentration curve from time 0 to the last measurable plasma concentration time point, up to 72 hours.</description>
          <population>All 12 subjects received each treatment</population>
          <units>ng/mL*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6142.1" spread="2845.9"/>
                    <measurement group_id="O2" value="5765.7" spread="3036.6"/>
                    <measurement group_id="O3" value="11094.2" spread="4209.0"/>
                    <measurement group_id="O4" value="9252.0" spread="4217.5"/>
                    <measurement group_id="O5" value="9576.2" spread="4328.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Proellex</title>
        <description>Time to maximum plasma occurrence of Cmax</description>
        <time_frame>Up to 72 hours post dose</time_frame>
        <population>All 12 subjects received each treatment</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg AMCC Fed</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O2">
            <title>25 mg AMCC Fasting</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O3">
            <title>50 mg AMCC Fed</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O4">
            <title>50 mg AMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O5">
            <title>50 mg SMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose Fasting State</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Proellex</title>
          <description>Time to maximum plasma occurrence of Cmax</description>
          <population>All 12 subjects received each treatment</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.6"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                    <measurement group_id="O3" value="2.6" spread="1.0"/>
                    <measurement group_id="O4" value="0.9" spread="0.4"/>
                    <measurement group_id="O5" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-infinity of Proellex</title>
        <description>Area under the plasma concentration curve from time 0 to extrapolated to infinity, calculated by summing the area under the curve from time zero to the time of the last quantifiable concentration</description>
        <time_frame>Up to 72 hours post dose</time_frame>
        <population>All 12 subjects received each treatment</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg AMCC Fed</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O2">
            <title>25 mg AMCC Fasting</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O3">
            <title>50 mg AMCC Fed</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O4">
            <title>50 mg AMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O5">
            <title>50 mg SMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose Fasting State</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity of Proellex</title>
          <description>Area under the plasma concentration curve from time 0 to extrapolated to infinity, calculated by summing the area under the curve from time zero to the time of the last quantifiable concentration</description>
          <population>All 12 subjects received each treatment</population>
          <units>ng/mL*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7039.8" spread="3715.6"/>
                    <measurement group_id="O2" value="6897.0" spread="4440.7"/>
                    <measurement group_id="O3" value="13014.9" spread="6753.2"/>
                    <measurement group_id="O4" value="11271.6" spread="6726.6"/>
                    <measurement group_id="O5" value="11804.8" spread="7186.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) of Proellex</title>
        <description>Time to maximum plasma occurrence of T1/2, calculated as ln(2)/Elimination rate constant.</description>
        <time_frame>Up to 72 hours post dose</time_frame>
        <population>All 12 subjects received each treatment</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg AMCC Fed</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O2">
            <title>25 mg AMCC Fasting</title>
            <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O3">
            <title>50 mg AMCC Fed</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fed State</description>
          </group>
          <group group_id="O4">
            <title>50 mg AMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
          </group>
          <group group_id="O5">
            <title>50 mg SMCC Fasting</title>
            <description>Two, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose Fasting State</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) of Proellex</title>
          <description>Time to maximum plasma occurrence of T1/2, calculated as ln(2)/Elimination rate constant.</description>
          <population>All 12 subjects received each treatment</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="8.2"/>
                    <measurement group_id="O2" value="25.2" spread="10.4"/>
                    <measurement group_id="O3" value="23.8" spread="10.8"/>
                    <measurement group_id="O4" value="26.7" spread="11.8"/>
                    <measurement group_id="O5" value="27.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>25 mg AMCC Fed</title>
          <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fed State</description>
        </group>
        <group group_id="E2">
          <title>25 mg AMCC Fasting</title>
          <description>25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
        </group>
        <group group_id="E3">
          <title>50 mg AMCC Fed</title>
          <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fed State</description>
        </group>
        <group group_id="E4">
          <title>50 mg AMCC Fasting</title>
          <description>Two, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose Fasting State</description>
        </group>
        <group group_id="E5">
          <title>50 mg SMCC Fasting</title>
          <description>Two, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose Fasting State</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvi pain NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oligomenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Repros Therapeutics Inc, an Allergan Affiliate</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

